AstraZeneca: Mixed Results from Farxiga Trial
24 September 2018 - 4:44PM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) reported mixed results from a phase 3
clinical trial for its drug Farxiga, a treatment for cardiovascular
disease in patients with diabetes.
The pharmaceutical major said on Monday that Farxiga didn't meet
its efficacy objective of reducing major adverse cardiovascular
events in a statistically significant way.
However the treatment was effective in reducing hospitalization
for heart failure and cardiovascular death, the drug maker
said.
AstraZeneca said it will present detailed results from the
trial, called Declare, on Nov. 10.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
September 24, 2018 02:29 ET (06:29 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024